VRTX

458.99

1.28% 5.82

시간 외 거래: 456.01 -2.98 -0.65%

버텍스 파마슈티컬 (VRTX)

개요 뉴스 가격 이력 옵션 체인 Financials VRTX 왜 하락? 토론 예측 주식 분할

전일 마감가:

$453.17

열려 있는:

$449.67

하루 거래량:

1.52M

Relative Volume:

1.21

시가총액:

$116.49B

수익:

$12.34B

순이익/손실:

$4.34B

주가수익비율:

27.21

EPS:

16.8685

순현금흐름:

$3.71B

1주 성능:

+5.34%

1개월 성능:

+5.04%

6개월 성능:

+2.11%

1년 성능:

+3.85%

1일 변동 폭

$447.54

$464.31

1주일 범위

$435.21

$464.31

52주 변동 폭

$362.50

$507.92

버텍스 파마슈티컬 Stock (VRTX) Company Profile

명칭

Vertex Pharmaceuticals Inc

부문

Healthcare (1100)

산업

Biotechnology (615)

전화

(617) 341-6393

주소

50 NORTHERN AVENUE, BOSTON, MA

직원

6,400

트위터

@VertexPharma

다음 수익 날짜

2026-08-03

최신 SEC 제출 서류

VRTX's Discussions on Twitter

Compare VRTX vs REGN, ARGX, ALNY, RVMD

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-18	업그레이드	Maxim Group	Hold → Buy
2026-03-10	개시	Jefferies	Buy
2026-03-10	재확인	Oppenheimer	Outperform
2026-02-13	업그레이드	Oppenheimer	Perform → Outperform
2026-01-28	재개	Barclays	Overweight
2026-01-22	업그레이드	RBC Capital Mkts	Sector Perform → Outperform
2026-01-12	업그레이드	Bernstein	Mkt Perform → Outperform
2026-01-07	재개	UBS	Buy
2026-01-06	업그레이드	Wolfe Research	Peer Perform → Outperform
2025-12-03	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2025-11-13	개시	Scotiabank	Sector Outperform
2025-09-25	업그레이드	Leerink Partners	Market Perform → Outperform
2025-09-03	개시	Raymond James	Mkt Perform
2025-08-06	업그레이드	Wells Fargo	Equal Weight → Overweight
2025-05-07	다운그레이드	Wolfe Research	Outperform → Peer Perform
2025-05-06	다운그레이드	Leerink Partners	Outperform → Market Perform
2025-04-22	재개	Cantor Fitzgerald	Overweight
2025-02-12	업그레이드	Canaccord Genuity	Sell → Hold
2025-02-11	업그레이드	Canaccord Genuity	Sell → Hold
2025-01-30	다운그레이드	Wells Fargo	Overweight → Equal Weight
2024-12-20	재확인	H.C. Wainwright	Buy
2024-12-19	다운그레이드	Oppenheimer	Outperform → Perform
2024-12-09	업그레이드	Jefferies	Hold → Buy
2024-11-14	개시	Citigroup	Buy
2024-10-16	개시	Scotiabank	Sector Perform
2024-10-10	재개	Raymond James	Mkt Perform
2024-08-05	다운그레이드	Barclays	Overweight → Equal Weight
2024-06-27	개시	Redburn Atlantic	Buy
2024-04-11	업그레이드	Evercore ISI	In-line → Outperform
2024-02-15	개시	Wolfe Research	Outperform
2024-02-06	다운그레이드	Evercore ISI	Outperform → In-line
2024-02-02	다운그레이드	Bernstein	Outperform → Mkt Perform
2024-01-31	다운그레이드	Maxim Group	Buy → Hold
2024-01-31	다운그레이드	Robert W. Baird	Neutral → Underperform
2024-01-24	다운그레이드	Canaccord Genuity	Hold → Sell
2023-12-14	재확인	RBC Capital Mkts	Sector Perform
2023-05-30	개시	William Blair	Outperform
2023-05-04	재개	Piper Sandler	Overweight
2023-03-21	개시	Bernstein	Outperform
2023-01-18	개시	Canaccord Genuity	Hold
2023-01-17	업그레이드	SVB Leerink	Mkt Perform → Outperform
2022-12-19	다운그레이드	Jefferies	Buy → Hold
2022-07-13	개시	Cantor Fitzgerald	Overweight
2022-06-01	업그레이드	Maxim Group	Hold → Buy
2022-05-23	개시	SVB Leerink	Mkt Perform
2022-05-06	다운그레이드	Robert W. Baird	Outperform → Neutral
2022-05-03	업그레이드	Morgan Stanley	Underweight → Equal-Weight
2022-02-03	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2022-01-27	재확인	JP Morgan	Overweight
2022-01-27	재확인	Morgan Stanley	Underweight
2022-01-27	재확인	RBC Capital Mkts	Outperform
2022-01-27	재확인	Stifel	Hold
2022-01-27	재확인	Wolfe Research	Outperform
2022-01-20	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-12-09	개시	Wells Fargo	Overweight
2021-11-19	개시	BMO Capital Markets	Market Perform
2021-11-19	다운그레이드	Piper Sandler	Overweight → Neutral
2021-09-09	다운그레이드	Stifel	Buy → Hold
2021-09-07	다운그레이드	Morgan Stanley	Equal-Weight → Underweight
2021-07-20	다운그레이드	SVB Leerink	Mkt Perform → Underperform
2021-07-19	재개	Wolfe Research	Outperform
2021-07-01	개시	Raymond James	Mkt Perform
2021-06-11	다운그레이드	Daiwa Securities	Outperform → Neutral
2021-02-23	업그레이드	Robert W. Baird	Neutral → Outperform
2021-02-02	재확인	H.C. Wainwright	Buy
2020-12-30	개시	Daiwa Securities	Outperform
2020-11-30	업그레이드	RBC Capital Mkts	Sector Perform → Outperform
2020-11-20	개시	Bernstein	Outperform
2020-10-28	개시	UBS	Buy
2020-07-31	재확인	H.C. Wainwright	Buy
2020-07-08	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2020-04-30	재확인	H.C. Wainwright	Buy
2020-04-28	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2020-03-04	개시	Barclays	Overweight
2020-01-31	다운그레이드	Robert W. Baird	Outperform → Neutral
2019-11-19	업그레이드	Guggenheim	Neutral → Buy
2019-11-12	개시	SunTrust	Buy
2019-10-17	재개	BofA/Merrill	Buy
2019-09-03	업그레이드	Goldman	Neutral → Buy
2019-08-01	다운그레이드	Needham	Buy → Hold
2019-05-23	재개	Citigroup	Buy
2019-05-21	개시	Credit Suisse	Outperform
2019-04-12	개시	Evercore ISI	In-line
2019-03-26	업그레이드	William Blair	Mkt Perform → Outperform
2019-03-19	다운그레이드	SVB Leerink	Outperform → Mkt Perform
2019-02-06	다운그레이드	Maxim Group	Buy → Hold

모두보기

버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스

Jun 15, 2026

Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market - MarketWatch

Jun 15, 2026

Vertex Pharma (NASDAQ: VRTX) notice: 4,062 shares proposed for resale on 06/15/2026 - Stock Titan

Jun 15, 2026

Vertex Pharma Stock (US92532F1003): Wall Street Analysts Lift Targets After VX-548 Progress - AD HOC NEWS

Jun 15, 2026

Jun 14, 2026

Vertex Pharma Stock (US92532F1003): Analyst sentiment and ownership moves keep VRTX in focus - AD HOC NEWS

Jun 14, 2026

Jun 13, 2026

Is It Time to Buy This Turnaround Pharma Stock? - NAI500

Jun 13, 2026

Jun 12, 2026

Vertex Pharmaceuticals (VRTX) Receives a Buy from Wells Fargo - The Globe and Mail

Jun 12, 2026

Swiss National Bank Reduces Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jun 12, 2026

Meiji Yasuda America Inc Invests $1.91 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jun 12, 2026

Aviva PLC Buys 11,322 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jun 12, 2026

Vertex Extends Pediatric Pipeline As Shares Trade Below Consensus Targets - Yahoo Finance

Jun 12, 2026

Jun 11, 2026

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts - Yahoo Finance Singapore

Jun 11, 2026

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Jun 11, 2026

Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now? - Insider Monkey

Jun 11, 2026

Vertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders - Benzinga

Jun 11, 2026

Goldman Sachs Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $641 - Moomoo

Jun 11, 2026

Vertex CASGEVY pediatric data shows 100% success in CRISPR trials - grafa.com

Jun 11, 2026

Zions Bancorporation National Association UT Grows Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jun 11, 2026

Vertex Pharmaceuticals (VRTX) Reports Positive Data for Casgevy in Pediatrics - GuruFocus

Jun 11, 2026

Illinois Municipal Retirement Fund Reduces Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jun 11, 2026

LPL Financial LLC Has $125.53 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jun 11, 2026

Fierce Biotech Layoff Tracker 2026: Genentech trims R&D; Fulcrum shrinks headcount 85% - Fierce Biotech

Jun 11, 2026

MFS Blended Research Core Equity Portfolio's Vertex Pharmaceuticals Inc(VRTX) Holding History - GuruFocus

Jun 11, 2026

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions - Yahoo Finance

Jun 11, 2026

Jun 10, 2026

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance

Jun 10, 2026

Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Jun 10, 2026

Vertex Pharmaceuticals stock (US92532F1003): Insider sale draws attention amid strong biotech pipeli - AD HOC NEWS

Jun 10, 2026

VRTX: Pipeline momentum in CF, pain, and kidney disease drives innovation-led growth outlook - TradingView

Jun 10, 2026

VRTX: Expanding CF, pain, and renal franchises with robust late-stage pipeline and innovation focus - TradingView

Jun 10, 2026

Vertex Pharma stock (US92532F1003): focus on cystic fibrosis growth and pipeline potential - AD HOC NEWS

Jun 10, 2026

Motley Fool Asset Management LLC Has $10.70 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jun 10, 2026

Motley Fool Wealth Management LLC Decreases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jun 10, 2026

Franklin Resources Inc. Increases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jun 10, 2026

Deutsche Bank AG Has $801.94 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jun 10, 2026

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Jun 10, 2026

Jun 09, 2026

Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus

Jun 09, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Carmen Bozic Sells 1,745 Shares - MarketBeat

Jun 09, 2026

Vertex Pharmaceuticals Insider Sold Shares Worth $785,250, According to a Recent SEC Filing - marketscreener.com

Jun 09, 2026

Vertex Pharmaceuticals (VRTX) EVP and CMO sells 1,745 shares in planned trade - Stock Titan

Jun 09, 2026

Can Vertex Pharmaceuticals Deepen Its Cystic Fibrosis Edge? - Kalkine Media

Jun 09, 2026

O Shaughnessy Asset Management LLC Buys 11,564 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jun 09, 2026

Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Cerity Partners LLC - MarketBeat

Jun 09, 2026

Jun 08, 2026

Kyverna vs. Vertex: Clinical-Stage Risk vs. Cash-Flow Stability in Biotech InvestingNews and Statistics - IndexBox

Jun 08, 2026

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? - The Motley Fool

Jun 08, 2026

Membranous Nephropathy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Roche, BeOne Medicines, Biogen, Vertex Pharma, AstraZeneca, Alexion Pharma, Climb Bio - Barchart.com

Jun 08, 2026

Vertex Pharmaceuticals (VRTX) Stock Analysis: Uncovering A 22.80% Potential Upside - DirectorsTalk Interviews

Jun 08, 2026

Jun 07, 2026

News | Not built for eternity: Design technique looks to avoid permanence - CoStar

Jun 07, 2026

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference - BioSpace

Jun 07, 2026

WINTON GROUP Ltd Purchases New Shares in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jun 07, 2026

ING Groep NV Has $36.78 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jun 07, 2026

Clearbridge Investments LLC Grows Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Jun 07, 2026

Vertex Pharmaceuticals Incorporated $VRTX is Capital World Investors' 10th Largest Position - MarketBeat

Jun 07, 2026